Behrend E - Search Results

1

Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression.

Radeva G, Petrocelli T, Behrend E, Leung-Hagesteijn C, Filmus J, Slingerland J, Dedhar S. Radeva G, et al. Among authors: behrend e. J Biol Chem. 1997 May 23;272(21):13937-44. doi: 10.1074/jbc.272.21.13937. J Biol Chem. 1997. PMID: 9153256 Free article.

2

Comparative analysis of two alternative first exons reported for the mouse osteopontin gene.

Behrend EI, Chambers AF, Wilson SM, Denhardt DT. Behrend EI, et al. J Biol Chem. 1993 May 25;268(15):11172-5. J Biol Chem. 1993. PMID: 7684372 Free article.

3

Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase.

Berg RW, Werner M, Ferguson PJ, Postenka C, Vincent M, Koropatnick DJ, Behrend E. Berg RW, et al. Among authors: behrend e. J Pharmacol Exp Ther. 2001 Aug;298(2):477-84. J Pharmacol Exp Ther. 2001. PMID: 11454908

4

Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells.

Chambers AF, Behrend EI, Wilson SM, Denhardt DT. Chambers AF, et al. Among authors: behrend ei. Anticancer Res. 1992 Jan-Feb;12(1):43-7. Anticancer Res. 1992. PMID: 1567180

5

Expression of antisense osteopontin RNA in metastatic mouse fibroblasts is associated with reduced malignancy.

Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF. Behrend EI, et al. Ann N Y Acad Sci. 1995 Apr 21;760:299-301. doi: 10.1111/j.1749-6632.1995.tb44640.x. Ann N Y Acad Sci. 1995. PMID: 7785904 No abstract available.

6

Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA.

Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF. Behrend EI, et al. Cancer Res. 1994 Feb 1;54(3):832-7. Cancer Res. 1994. PMID: 8306346

7

[CT-scan in the emergency department : the right indications, the right timing].

Behrend E, Schellongova M, Abi-Khalil M. Behrend E, et al. Rev Med Suisse. 2024 Aug 21;20(883):1391-1395. doi: 10.53738/REVMED.2024.20.883.1391. Rev Med Suisse. 2024. PMID: 39175286 French.

8

Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study.

Behrend EN, Ward CR, Chukwu V, Cook AK, Kroh C, Lathan P, May J, Schermerhorn T, Scott-Moncrieff JC, Voth R. Behrend EN, et al. J Am Vet Med Assoc. 2024 Aug 14;262(10):1343-1353. doi: 10.2460/javma.24.03.0174. Print 2024 Oct 1. J Am Vet Med Assoc. 2024. PMID: 39142336

9

SGLT2 inhibitor use in the management of feline diabetes mellitus.

Cook AK, Behrend E. Cook AK, et al. Among authors: behrend e. J Vet Pharmacol Ther. 2024 Jul 2. doi: 10.1111/jvp.13466. Online ahead of print. J Vet Pharmacol Ther. 2024. PMID: 38954371 Review.

10

The impact of single-dose trazodone administration on plasma endogenous adrenocorticotropic hormone and serum cortisol concentrations in healthy dogs.

Brown M, Lee-Fowler T, Behrend EN, Grobman M. Brown M, et al. Among authors: behrend en. J Vet Intern Med. 2024 Jan-Feb;38(1):130-134. doi: 10.1111/jvim.16935. Epub 2023 Nov 15. J Vet Intern Med. 2024. PMID: 37965773 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

96 results

Search Page

Filters